To better evaluate the potential clinical utility of fecal zonulin in MASLD, we examined its ability to distinguish cases of moderate-to-severe hepatic steatosis (SteatoTest ≥ S2) through receiver operating characteristic (ROC) analysis. This evidence concerns the gene HP and Hepatic steatosis.